Analyzing Pakistan's Export Performance to China Under the FTA: Does Tariff Recession Matter?
Frontiers of Finance · 2025
DOI: 10.59429/ff.v3i1.12000 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers of Finance, 2025. Verfasst von Zeeshan Iqbal und 2 weiteren Autor:innen.
Abstract (Originalsprache)
The China-Pakistan FTA, contracted in 2006, has significantly influenced the dynamics of bilateral trade among China and Pakistan. Established on aggregated panel data of 150 commodities from 2007 and 2023, this paper examines the effect of tariff reduction and trade facilitation costs of Pakistani exports to China according to the offer list offered by China. The gravity model and advanced econometric techniques are used, and it has been identified that the FTA and trade reduction models positively affected Pakistan's export trajectory. Additionally, trade improvements were initiated by reducing trade facilitation costs for Exports and imports per container. The recommendations in this study considered ways to best realize the advantages of the FTA by decreasing trade barriers and capitalizing on industrial competitiveness, along with the Belt and Road Initiative (OBOR), especially for Pakistan, to promote their domestic industries. Such results provide policymakers with insights for improving bilateral trade ties and resolving the current trade imbalance.
Zitieren
APA
Iqbal, Z., Ahmad, S., & Ahmad, I. (2025). Analyzing Pakistan's Export Performance to China Under the FTA: Does Tariff Recession Matter?. Frontiers of Finance. https://doi.org/10.59429/ff.v3i1.12000
Vancouver
Iqbal Z, Ahmad S, Ahmad I. Analyzing Pakistan's Export Performance to China Under the FTA: Does Tariff Recession Matter?. Frontiers of Finance. 2025. doi:10.59429/ff.v3i1.12000
BibTeX
@article{Iqbal2025,
author = {Iqbal, Zeeshan and Ahmad, Shahzad and Ahmad, Imad},
title = {Analyzing Pakistan's Export Performance to China Under the FTA: Does Tariff Recession Matter?},
journal = {Frontiers of Finance},
year = {2025},
doi = {10.59429/ff.v3i1.12000}
}
EUVIMED